What is AdAlta?
AdAlta is a biotechnology firm dedicated to pioneering innovative treatments for severe diseases. Leveraging its proprietary i-body® drug discovery platform, the company addresses therapeutic gaps where conventional antibodies are insufficient. AdAlta's core focus lies in next-generation protein and cell therapies, with specific emphasis on fibrotic conditions and immuno-oncology. The company's lead asset, AD-214, is a first-in-class therapeutic candidate designed for fibrotic diseases and holds potential for treating solid tumors. Furthermore, AdAlta is advancing i-CAR-T cell therapies and i-PET imaging technologies to enhance the efficacy of cancer treatments.
How much funding has AdAlta raised?
AdAlta has raised a total of $2.1M across 2 funding rounds:
Other Financing Round
$325K
Stock/Share Issuance
$1.8M
Other Financing Round (2025): $325K, investors not publicly disclosed
Stock/Share Issuance (2026): $1.8M, investors not publicly disclosed
What's next for AdAlta?
The substantial enterprise-level investment AdAlta has attracted signals a critical growth phase, likely focused on advancing its pipeline assets, particularly AD-214, through late-stage clinical trials and expanding its i-body® platform applications. This strategic financing is expected to bolster the company's capabilities in protein and cell therapies, aiming to solidify its position in the competitive fibrosis and immuno-oncology markets. Future developments will likely involve strategic partnerships and further validation of its innovative drug discovery technologies.
See full AdAlta company page
